Suppr超能文献

急性肺栓塞全因死亡与肺栓塞相关死亡的危险因素差异:来自COMMAND VTE注册研究-2的见解

Differences in risk factors between all-cause and pulmonary embolism-related death in acute pulmonary embolism: insights from the COMMAND VTE registry-2.

作者信息

Kobayashi Soichiro, Ogihara Yoshito, Yamashita Yugo, Morimoto Takeshi, Chatani Ryuki, Kaneda Kazuhisa, Nishimoto Yuji, Ikeda Nobutaka, Kobayashi Yohei, Ikeda Satoshi, Kim Kitae, Inoko Moriaki, Takase Toru, Tsuji Shuhei, Oi Maki, Takada Takuma, Otsui Kazunori, Sakamoto Jiro, Inoue Takeshi, Usami Shunsuke, Chen Po-Min, Togi Kiyonori, Koitabashi Norimichi, Hiramori Seiichi, Doi Kosuke, Mabuchi Hiroshi, Tsuyuki Yoshiaki, Murata Koichiro, Takabayashi Kensuke, Nakai Hisato, Sueta Daisuke, Shioyama Wataru, Dohke Tomohiro, Sato Toru, Nishikawa Ryusuke, Kimura Takeshi, Dohi Kaoru

机构信息

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.

Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Res Pract Thromb Haemost. 2025 Jul 3;9(5):102965. doi: 10.1016/j.rpth.2025.102965. eCollection 2025 Jul.

Abstract

BACKGROUND

Accurate risk prediction of early mortality, particularly pulmonary embolism (PE)-related death, in patients with acute PE has become more important for selecting optimal management strategies.

OBJECTIVES

To evaluate the cumulative 30-day incidence of and risk factors for all-cause and PE-related death within 30 days.

METHODS

In the COMMAND VTE Registry-2, which enrolled symptomatic patients with venous thromboembolism at 31 centers in Japan, we analyzed 2035 patients with acute PE.

RESULTS

The cumulative 30-day incidence of all-cause and PE-related death was 6.4% and 3.4%, respectively. Independent risk factors for all-cause and PE-related death were age >80 years (hazard ratio [HR], 2.43; 95% CI, 1.45-4.08; < .001), hypoxemia (HR, 3.36; 95% CI, 1.07-10.5; = .04), tachycardia (HR, 3.78; 95% CI, 2.20-6.50; < .001), hypotension (HR, 5.43; 95% CI, 3.17-9.29; < .001), an abnormal leukocyte count (HR, 1.78; 95% CI, 1.08-2.93; = .02), and the absence of proximal deep vein thrombosis (HR, 2.58; 95% CI, 1.51-4.39; < .001). Active cancer (HR, 2.59; 95% CI, 1.75-3.82; < .001) and male sex (HR, 1.56; 95% CI, 1.07-2.28; = .02) were independent risk factors for all-cause death, but not PE-related death. Chronic heart or lung disease (HR, 1.72; 95% CI, 1.02-2.90; = .04) and right ventricular dysfunction (HR, 2.61; 95% CI, 1.02-6.70; = .046) were independent risk factors for PE-related death, but not all-cause death.

CONCLUSION

We identified several independent risk factors for PE-related death within 30 days, which differed from those of all-cause death. Risk factors specifically for PE-related death may be useful in decision-making for optimal treatment strategies for acute PE.

摘要

背景

准确预测急性肺栓塞(PE)患者的早期死亡率,尤其是与PE相关的死亡,对于选择最佳治疗策略变得更加重要。

目的

评估30天内全因死亡和PE相关死亡的累积发生率及危险因素。

方法

在COMMAND VTE注册研究-2中,该研究纳入了日本31个中心有症状的静脉血栓栓塞患者,我们分析了2035例急性PE患者。

结果

全因死亡和PE相关死亡的30天累积发生率分别为6.4%和3.4%。全因死亡和PE相关死亡的独立危险因素为年龄>80岁(风险比[HR],2.43;95%置信区间[CI],1.45-4.08;P<0.001)、低氧血症(HR,3.36;95%CI,1.07-10.5;P = 0.04)、心动过速(HR,3.78;95%CI,2.20-6.50;P<0.001)、低血压(HR,5.43;95%CI,3.17-9.29;P<0.001)、白细胞计数异常(HR,1.78;95%CI,1.08-2.93;P = 0.02)以及无近端深静脉血栓形成(HR,2.58;95%CI,1.51-4.39;P<0.001)。活动性癌症(HR,2.59;95%CI,1.75-3.82;P<0.001)和男性(HR,1.56;95%CI,1.07-2.28;P = 0.02)是全因死亡的独立危险因素,但不是PE相关死亡的危险因素。慢性心肺疾病(HR,1.72;95%CI,1.02-2.90;P = 0.04)和右心室功能障碍(HR,2.61;95%CI,1.02-6.70;P = 0.046)是PE相关死亡的独立危险因素,但不是全因死亡的危险因素。

结论

我们确定了30天内与PE相关死亡的几个独立危险因素,这些因素与全因死亡的危险因素不同。专门针对PE相关死亡的危险因素可能有助于为急性PE的最佳治疗策略决策提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c30d/12336812/f8a3614d6665/gr1.jpg

相似文献

1
Differences in risk factors between all-cause and pulmonary embolism-related death in acute pulmonary embolism: insights from the COMMAND VTE registry-2.
Res Pract Thromb Haemost. 2025 Jul 3;9(5):102965. doi: 10.1016/j.rpth.2025.102965. eCollection 2025 Jul.
2
Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism.
Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD013835. doi: 10.1002/14651858.CD013835.pub2.
4
5
Prophylactic anticoagulants for non-hospitalised people with COVID-19.
Cochrane Database Syst Rev. 2023 Aug 16;8(8):CD015102. doi: 10.1002/14651858.CD015102.pub2.
6
7
Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients.
Cochrane Database Syst Rev. 2024 Dec 4;12(12):CD014541. doi: 10.1002/14651858.CD014541.pub2.
8
Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.
Cochrane Database Syst Rev. 2022 Nov 22;11(11):CD013683. doi: 10.1002/14651858.CD013683.pub2.
9
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Cochrane Database Syst Rev. 2017 Feb 14;2(2):CD006771. doi: 10.1002/14651858.CD006771.pub3.
10
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Cochrane Database Syst Rev. 2017 Aug 23;8(8):CD010837. doi: 10.1002/14651858.CD010837.pub3.

本文引用的文献

1
Predicting Short-Term Mortality in Patients With Acute Pulmonary Embolism With Deep Learning.
Circ J. 2025 Apr 25;89(5):602-611. doi: 10.1253/circj.CJ-24-0630. Epub 2024 Nov 30.
4
Prognostic value of pulmonary artery diameter/aorta diameter ratio in patients with acute pulmonary embolism.
Herz. 2024 Dec;49(6):464-471. doi: 10.1007/s00059-024-05251-4. Epub 2024 Jun 4.
5
Evaluation of Naples prognostic score to predict long-term mortality in patients with pulmonary embolism.
Biomark Med. 2024;18(6):253-263. doi: 10.2217/bmm-2023-0741. Epub 2024 Mar 15.
6
7
The Role of Artificial Intelligence in Coronary Artery Disease and Atrial Fibrillation.
Balkan Med J. 2023 May 8;40(3):151-152. doi: 10.4274/balkanmedj.galenos.2023.06042023. Epub 2023 Apr 7.
8
Causes of long-term mortality in patients with venous thromboembolism in the real world: From the COMMAND VTE registry.
Thromb Res. 2022 Nov;219:30-39. doi: 10.1016/j.thromres.2022.09.002. Epub 2022 Sep 7.
9
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
Chest. 2021 Dec;160(6):2247-2259. doi: 10.1016/j.chest.2021.07.056. Epub 2021 Aug 2.
10
Sex differences in presentation, management, and outcomes among patients hospitalized with acute pulmonary embolism.
Vasc Med. 2020 Dec;25(6):541-548. doi: 10.1177/1358863X20964577. Epub 2020 Nov 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验